About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Fto
FTO alpha-ketoglutarate dependent dioxygenase
MGI:1347093
62 phenotypes from 10 alleles in 9 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
FtoGt(RRZ624)Byg/FtoGt(RRZ624)Byg
involves: 129P2/OlaHsd 		normal growth/size/body region phenotype J:166984
FtoI367F/Fto+
involves: C3H/HeH * C57BL/6J 		abnormal metabolism J:152163
decreased body weight J:152163
decreased percent body fat/body weight J:152163
decreased total body fat amount J:152163
increased carbon dioxide production J:152163
increased oxygen consumption J:152163
increased respiratory quotient J:152163
FtoI367F/FtoI367F
involves: C3H/HeH * C57BL/6J 		abnormal metabolism J:152163
abnormal urine catecholamine level J:152163
decreased body weight J:152163
decreased carbon dioxide production J:152163
decreased circulating insulin level J:152163
decreased percent body fat/body weight J:152163
decreased total body fat amount J:152163
increased carbon dioxide production J:152163
increased circulating cholesterol level J:152163
increased circulating glucagon level J:152163
increased circulating glucose level J:152163
increased circulating HDL cholesterol level J:152163
increased circulating leptin level J:152163
increased circulating triglyceride level J:152163
increased lean body mass J:152163
increased oxygen consumption J:152163
increased respiratory quotient J:152163
Ftotm1.1Pzg/Ftotm1.1Pzg
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * SJL 		abnormal carbon dioxide production J:166984
abnormal eating behavior J:166984
abnormal oxygen consumption J:166984
decreased body length J:166984
decreased bone mineral density J:166984
decreased circulating insulin-like growth factor I level J:166984
decreased lean body mass J:166984
postnatal growth retardation J:166984
Ftotm1.1Rdc/Ftotm1.1Rdc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 		decreased body weight J:194922
decreased food intake J:194922
normal homeostasis/metabolism phenotype J:194922
Ftotm1.1Rdc/Ftotm1.1Rdc
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL 		decreased body weight J:194922
decreased carbon dioxide production J:194922
decreased lean body mass J:194922
decreased respiratory quotient J:194922
normal homeostasis/metabolism phenotype J:194922
increased total body fat amount J:194922
premature death J:194922
Ftotm1.2Pzg/Ftotm1.2Pzg
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 		abnormal carbon dioxide production J:166984
abnormal eating behavior J:166984
abnormal oxygen consumption J:166984
cachexia J:166984
decreased body length J:166984
decreased body weight J:166984
decreased bone mineral density J:166984
decreased circulating insulin-like growth factor I level J:166984
decreased lean body mass J:166984
dermatitis J:166984
increased susceptibility to diet-induced obesity J:166984
increased total body fat amount J:166984
postnatal growth retardation J:166984
postnatal lethality, incomplete penetrance J:166984
Ftotm1.2Rdc/Ftotm1.2Rdc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6J * SJL 		decreased body weight J:194922
decreased lean body mass J:194922
decreased respiratory quotient J:194922
normal homeostasis/metabolism phenotype J:194922
improved glucose tolerance J:194922
increased food intake J:194922
increased oxygen consumption J:194922
preweaning lethality, incomplete penetrance J:194922
Ftotm1.3Pzg/Ftotm1.3Pzg
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 		abnormal carbon dioxide production J:166984
abnormal eating behavior J:166984
abnormal oxygen consumption J:166984
cachexia J:166984
decreased body length J:166984
decreased body weight J:166984
decreased bone mineral density J:166984
decreased circulating insulin-like growth factor I level J:166984
decreased lean body mass J:166984
dermatitis J:166984
increased susceptibility to diet-induced obesity J:166984
increased total body fat amount J:166984
postnatal growth retardation J:166984
postnatal lethality, incomplete penetrance J:166984
Ftotm1a(EUCOMM)Wtsi/Ftotm1a(EUCOMM)Wtsi
B6JTyr;B6N-Ftotm1a(EUCOMM)Wtsi/Wtsi 		decreased body weight J:165965
decreased circulating alanine transaminase level J:175295
decreased circulating aspartate transaminase level J:175295
decreased circulating iron level J:175295
decreased circulating LDL cholesterol level J:175295
decreased lactate dehydrogenase level J:175295
hyperactivity J:175295
Ftotm1Urt/Fto+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 		decreased susceptibility to diet-induced obesity J:147471
Ftotm1Urt/Ftotm1Urt
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 		abnormal circulating hormone level J:147471
decreased body length J:147471
decreased body weight J:147471
decreased circulating leptin level J:147471
decreased gonadal fat pad weight J:147471
decreased lean body mass J:147471
decreased locomotor activity J:147471
decreased susceptibility to diet-induced obesity J:147471
decreased total body fat amount J:147471
decreased white fat cell size J:147471
increased basal metabolism J:147471
increased carbon dioxide production J:147471
increased circulating adrenaline level J:147471
increased energy expenditure J:147471
increased oxygen consumption J:147471
polyphagia J:147471
postnatal growth retardation J:147471
postnatal lethality, incomplete penetrance J:147471
Gt(ROSA)26Sortm1.1(CAG-Fto)Rdc/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL 		abnormal circulating lipid level J:166829
abnormal hormone level J:166829
decreased adiponectin level J:166829
decreased circulating LDL cholesterol level J:166829
increased abdominal fat pad weight J:166829
increased body weight J:166829
increased circulating free fatty acids level J:166829
increased circulating HDL cholesterol level J:166829
increased circulating leptin level J:166829
increased circulating triglyceride level J:166829
increased food intake J:166829
increased lean body mass J:166829
increased susceptibility to diet-induced obesity J:166829
increased total body fat amount J:166829
Gt(ROSA)26Sortm1.1(CAG-Fto)Rdc/Gt(ROSA)26Sortm1.1(CAG-Fto)Rdc
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL 		abnormal circulating lipid level J:166829
abnormal hormone level J:166829
decreased adiponectin level J:166829
decreased circulating LDL cholesterol level J:166829
decreased circulating leptin level J:166829
impaired glucose tolerance J:166829
increased abdominal fat pad weight J:166829
increased body weight J:166829
increased circulating free fatty acids level J:166829
increased circulating HDL cholesterol level J:166829
increased circulating insulin level J:166829
increased circulating triglyceride level J:166829
increased energy expenditure J:166829
increased food intake J:166829
increased lean body mass J:166829
increased susceptibility to diet-induced obesity J:166829
increased total body fat amount J:166829
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
04/23/2024
MGI 6.23 		The Jackson Laboratory